Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesOphthalmology/Optometrymhn Acoltremon (Tryptyr) Prior Auth Coverage | Ope…
    Ask Trek AI about this page
    CurrentmhnPolicy CP.PHAR.739

    Acoltremon (Tryptyr) for dry eye disease

    Customize your policy alerts

    Sign up for mhn Policy CP.PHAR.739 alerts

    Get alerted when Policy CP.PHAR.739 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs medical necessity and prior authorization criteria for Acoltremon (Tryptyr) when used to treat signs and symptoms of dry eye disease for affected health plan members across listed lines of business.

    Policy Summary
    Payermhn
    PolicyAcoltremon (Tryptyr) for dry eye disease
    Policy CodePolicy CP.PHAR.739
    Change TypeNo material change
    Effective DateSep 1, 2025
    Next Review Date
    Key ActionSubmit prior authorization with documentation showing member meets all approval criteria, including age, prior therapy failures, and requested quantity limits.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    DEDFDA-approved indication
    Adults ≥18age restriction in approval criteria
    60 vialsmaximum request per 30 days
    12 monthsapproval duration
    State precedence

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Medicaid override

    Coverage Criteria

    Initial Therapy (Dry Eye Disease)

    Covered when ALL of the following are met:

    Initial Approval - DED: 1. Diagnosis of dry eye disease (DED); 2. Age ≥ 18 years; 3. Failure of an artificial tears agent unless clinically significant adverse effects or contraindications; 4. Failure of at least one ophthalmic anti-inflammatory agent at up to maximally indicated doses unless clinically significant adverse effects or contraindications; 5. Failure of generic ophthalmic cyclosporine emulsion 0.05% (generic Restasis) unless clinically significant adverse effects or contraindications; 6. Requested quantity does not exceed 60 vials (1 carton) per 30 days.≤ 60 vials (1 carton) per 30 days

    Illinois HIM requests: step therapy requirements do not apply per IL HB 5395

    Continuation Therapy (Dry Eye Disease)

    Continued therapy covered when ALL of the following are met:

    Continued Therapy - DED: 1. Member meets one of the following: (a) currently receiving medication via Centene benefit or previously met initial approval criteria, OR (b) currently receiving medication and enrolled in a state/product with continuity of care regulations; 2. Member is responding positively to therapy; 3. If request is for a dose increase, the request does not exceed 60 vials (1 carton) per 30 days.≤ 60 vials (1 carton) per 30 days

    Approval duration: 12 months

    Other Diagnoses/Indications

    For diagnoses/uses not specified:

    Other indications: 1. If the drug has undergone a recent label change (within the last 6 months) not yet reflected in this policy, follow the applicable no-coverage or non-formulary policy for the relevant line of business as specified in the policy (see CP.CPA.190, HIM.PA.33, CP.PMN.255, HIM.PA.103, CP.PMN.16); 2. If the requested use is not listed under section III (Diagnoses/Indications for which coverage is NOT authorized) and criterion 1 does not apply, refer to the off-label use policy for the relevant line of business (CP.CPA.09 for commercial, HIM.PA.154 for health insurance marketplace/ICHRA, CP.PMN.53 for Medicaid).

    References to specific line-of-business policies for non-standard uses

    Non–FDA approved indications for Acoltremon (Tryptyr) are not authorized unless the request includes sufficient documentation of safety and efficacy in accordance with the applicable off‑label use policies (see CP.CPA.09 for commercial, HIM.PA.154 for marketplace/ICHRA, and CP.PMN.53 for Medicaid) or as otherwise supported by evidence of coverage documents.

    When state Medicaid coverage provisions conflict with this clinical policy, state Medicaid coverage provisions take precedence. Providers should consult the applicable state Medicaid manual for specific coverage requirements and follow those provisions for Medicaid members.

    Use of Acoltremon for non‑FDA‑approved indications without submission of sufficient supporting documentation as required by the referenced off‑label use policies (CP.CPA.09, HIM.PA.154, CP.PMN.53) would be considered not authorized under this policy.

    Product Coding and Limits

    Product availability / NDCNDC
    NDC not listedProduct: Ophthalmic solution single-dose vial 0.003%, 0.4 mL; 60 vials/carton
    inv-08: Maximum vials per 30 days — ≤ 60 vials (1 carton) per 30 days
    Maximum allowed supply≤ 60 vials (1 carton) per 30 days
    Approval duration for requestsApproval duration: 12 months
    Dosage regimen referenceDED dosing: 1 drop in each eye BID (maximum 2 drops/day in each eye)

    Provider Actions and Authorization

    Prior Authorization

    Prior authorization required

    Prior authorization is required for Acoltremon (Tryptyr). Approval is granted when all listed initial or continued therapy criteria are met; approvals are issued for 12 months.

    Prior Authorization

    Prior authorization requirement

    This clinical policy governs coverage decisions that may require prior authorization per the Health Plan; providers submitting claims and services are subject to the policy's terms and must follow the policy when requesting coverage.

    Step Therapy

    Step therapy requirements

    Step therapy requires documented failure of an artificial tears agent, an ophthalmic anti-inflammatory agent, and generic ophthalmic cyclosporine emulsion 0.05% (generic Restasis), unless contraindicated or clinically significant adverse effects occur.

    Background

    Acoltremon (Tryptyr) is a TRPM8 thermoreceptor agonist approved for treatment of signs and symptoms of dry eye disease (DED). Per American Academy of Ophthalmology guidance referenced in this policy, artificial tears are the standard initial therapy for DED; if inadequate, topical anti‑inflammatory agents (for example, cyclosporine or lifitegrast) are typical next steps prior to use of newer agents such as Acoltremon. Providers must follow the policy criteria for initial and continued therapy, including prior therapy requirements and documentation of clinical response.

    Definitions

    inv-18: dry eye disease — DED definition/key facts
    Definition (abbreviation)DED = dry eye disease
    Standard initial therapyPer AAO guidelines, artificial tears are the standard therapy for all severity of dry eyes
    Subsequent therapy stepsIf artificial tears are inadequate, trial ophthalmic anti-inflammatory agents (e.g., cyclosporine, lifitegrast, topical corticosteroids) per AAO guidance
    Age requirement noted in criteriaInitial approval requires age ≥ 18 years for DED indications
    Policy Summary
    Payermhn
    PolicyAcoltremon (Tryptyr) for dry eye disease
    Policy CodePolicy CP.PHAR.739
    Change TypeNo material change
    Effective DateSep 1, 2025
    Next Review Date
    Key ActionSubmit prior authorization with documentation showing member meets all approval criteria, including age, prior therapy failures, and requested quantity limits.
    SourceLink
    On This Page
    Coverage CriteriaProduct Coding and LimitsProvider Actions and AuthorizationBackgroundDefinitions
    • Illinois HIM requests are exempt from step therapy requirements per IL HB 5395.
    Note

    Provider submission details

    Submit prior authorization requests that clearly state diagnosis, age, prior therapies tried (including dates and agents), and the quantity requested to facilitate timely review.

    • Include documentation of failures or contraindications to required step therapies.
    • Ensure requested quantity does not exceed 60 vials (1 carton) per 30 days.
    Documentation Required

    Required documentation

    Provider must submit documentation (such as office chart notes, lab results, or other clinical information) supporting that the member has met all approval criteria.

    • Documentation should include evidence of diagnosis, age, prior therapy trials and outcomes, and current response to therapy for continuation requests.
    Note

    Provider contractual notice

    Providers, members, and their representatives are bound to the terms and conditions expressed in this clinical policy through their contracts; by providing services or submitting claims they agree to be bound by the policy terms.

    Denial Risk

    Denial triggers

    Requests that do not document that the member has met all approval criteria for dry eye disease (including age ≥18 years, required prior therapy failures or documented contraindications, and quantity limits) may be denied.

    • Requests exceeding 60 vials (1 carton) per 30 days may be denied.
    • Use for non‑FDA‑approved indications without sufficient off‑label documentation may be denied.
    Note

    State Medicaid precedence

    When state Medicaid coverage provisions conflict with this clinical policy, state Medicaid coverage provisions take precedence; failure to follow state Medicaid manual provisions may result in denial.

    • Refer to the applicable state Medicaid manual for coverage provisions.